Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 113

1.

Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy.

Walz J, Joniau S, Chun FK, Isbarn H, Jeldres C, Yossepowitch O, Chao-Yu H, Klein EA, Scardino PT, Reuther A, Poppel HV, Graefen M, Huland H, Karakiewicz PI.

BJU Int. 2011 Mar;107(5):765-770. doi: 10.1111/j.1464-410X.2010.09594.x. Epub 2010 Sep 28.

2.

Pathological findings and prostate-specific antigen outcomes after laparoscopic radical prostatectomy for high-risk prostate cancer.

Ploussard G, Salomon L, Allory Y, Terry S, Vordos D, Hoznek A, Abbou CC, Vacherot F, de la Taille A.

BJU Int. 2010 Jul;106(1):86-90. doi: 10.1111/j.1464-410X.2009.09080.x. Epub 2009 Nov 20.

3.

Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer.

Lughezzani G, Gallina A, Larcher A, Briganti A, Capitanio U, Suardi N, Lista G, Abrate A, Sangalli MN, Buffi N, Cestari A, Guazzoni G, Rigatti P, Montorsi F.

BJU Int. 2013 May;111(5):723-30. doi: 10.1111/j.1464-410X.2012.11114.x. Epub 2012 Apr 4.

4.

Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy.

Pierorazio PM, Ross AE, Lin BM, Epstein JI, Han M, Walsh PC, Partin AW, Pavlovich CP, Schaeffer EM.

BJU Int. 2012 Oct;110(8):1122-8. doi: 10.1111/j.1464-410X.2012.10986.x. Epub 2012 Feb 28.

5.

Laparoscopic radical prostatectomy monotherapy, a more aggressive yet less invasive option, is oncologically effective in selected men with high-risk prostate cancer having only one D'Amico risk factor: experience from an Asian tertiary referral center.

Tai HC, Lai MK, Huang CY, Wang SM, Huang KH, Chen CH, Chung SD, Chueh SC, Yu HJ, Pu YS.

J Endourol. 2014 Feb;28(2):165-71. doi: 10.1089/end.2013.0118. Epub 2013 Oct 17.

PMID:
23987245
6.

Does the time from biopsy to surgery affect biochemical recurrence after radical prostatectomy?

Boorjian SA, Bianco FJ Jr, Scardino PT, Eastham JA.

BJU Int. 2005 Oct;96(6):773-6.

7.

Is clinical stage T2c prostate cancer an intermediate- or high-risk disease?

Klaassen Z, Singh AA, Howard LE, Feng Z, Trock B, Terris MK, Aronson WJ, Cooperberg MR, Amling CL, Kane CJ, Partin A, Han M, Freedland SJ.

Cancer. 2015 May 1;121(9):1414-21. doi: 10.1002/cncr.29147. Epub 2014 Dec 9.

8.

Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.

Kupelian PA, Katcher J, Levin HS, Klein EA.

Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1043-52.

PMID:
9169811
9.

Prognostic significance of a positive surgical margin in pathologically organ-confined prostate cancer.

Ahyai SA, Zacharias M, Isbarn H, Steuber T, Eichelberg C, Köllermann J, Fisch M, Karakiewicz PI, Huland H, Graefen M, Chun FK.

BJU Int. 2010 Aug;106(4):478-83. doi: 10.1111/j.1464-410X.2009.09162.x. Epub 2010 Jan 29.

10.

Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.

Ploussard G, Agamy MA, Alenda O, Allory Y, Mouracade P, Vordos D, Hoznek A, Abbou CC, de la Taille A, Salomon L.

BJU Int. 2011 Jun;107(11):1748-54. doi: 10.1111/j.1464-410X.2010.09728.x. Epub 2010 Sep 30.

11.

Long-term cancer control outcomes in patients with clinically high-risk prostate cancer treated with robot-assisted radical prostatectomy: results from a multi-institutional study of 1100 patients.

Abdollah F, Sood A, Sammon JD, Hsu L, Beyer B, Moschini M, Gandaglia G, Rogers CG, Haese A, Montorsi F, Graefen M, Briganti A, Menon M.

Eur Urol. 2015 Sep;68(3):497-505. doi: 10.1016/j.eururo.2015.06.020. Epub 2015 Jun 26.

PMID:
26119559
12.
13.

Influence of statin use on clinicopathological characteristics of localized prostate cancer and outcomes obtained after radical prostatectomy: a single center study.

Cattarino S, Seisen T, Drouin SJ, Renard-Penna R, Leon P, Comperat E, Mozer P, Cussenot O, Rouprêt M.

Can J Urol. 2015 Apr;22(2):7703-8.

PMID:
25891333
14.

Long-term data on the survival of patients with prostate cancer treated with radical prostatectomy in the prostate-specific antigen era.

Isbarn H, Wanner M, Salomon G, Steuber T, Schlomm T, Köllermann J, Sauter G, Haese A, Heinzer H, Huland H, Graefen M.

BJU Int. 2010 Jul;106(1):37-43. doi: 10.1111/j.1464-410X.2009.09134.x. Epub 2009 Dec 11.

15.

Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy.

Fossati N, Karnes RJ, Cozzarini C, Fiorino C, Gandaglia G, Joniau S, Boorjian SA, Goldner G, Hinkelbein W, Haustermans K, Tombal B, Shariat S, Karakiewicz PI, Montorsi F, Van Poppel H, Wiegel T, Briganti A.

Eur Urol. 2016 Apr;69(4):728-33. doi: 10.1016/j.eururo.2015.10.009. Epub 2015 Oct 21.

PMID:
26497924
16.

Reassessment of the risk factors for biochemical recurrence in D'Amico intermediate-risk prostate cancer treated using radical prostatectomy.

Narita S, Mitsuzuka K, Tsuchiya N, Koie T, Kawamura S, Ohyama C, Tochigi T, Yamaguchi T, Arai Y, Habuchi T; Michinoku Japan Urological Cancer Study Group.

Int J Urol. 2015 Nov;22(11):1029-35. doi: 10.1111/iju.12898. Epub 2015 Aug 20.

17.

Implications of greater short-term PSA recurrence with laparoscopic as compared to retropubic radical prostatectomy for Japanese clinically localized prostate carcinomas.

Akita H, Okamura T, Ando R, Nagata D, Naruyama H, Yamada Y, Naiki T, Yasui T, Tozawa K, Kohri K.

Asian Pac J Cancer Prev. 2011;12(11):2959-61.

18.

Short (≤ 1 mm) positive surgical margin and risk of biochemical recurrence after radical prostatectomy.

Shikanov S, Marchetti P, Desai V, Razmaria A, Antic T, Al-Ahmadie H, Zagaja G, Eggener S, Brendler C, Shalhav A.

BJU Int. 2013 Apr;111(4):559-63. doi: 10.1111/j.1464-410X.2012.11340.x. Epub 2012 Jul 3.

19.

Oncologic outcomes at 10 years following robotic radical prostatectomy.

Diaz M, Peabody JO, Kapoor V, Sammon J, Rogers CG, Stricker H, Lane Z, Gupta N, Bhandari M, Menon M.

Eur Urol. 2015 Jun;67(6):1168-76. doi: 10.1016/j.eururo.2014.06.025. Epub 2014 Jul 2.

PMID:
24996687
20.

Preoperative predictive factors and further risk stratification of biochemical recurrence in clinically localized high-risk prostate cancer.

Hamada R, Nakashima J, Ohori M, Ohno Y, Komori O, Yoshioka K, Tachibana M.

Int J Clin Oncol. 2016 Jun;21(3):595-600. doi: 10.1007/s10147-015-0923-3. Epub 2015 Nov 19. Erratum in: Int J Clin Oncol. 2016 Jun;21(3):601.

PMID:
26585896

Supplemental Content

Support Center